SOPHiA GENETICS Q3 EPS Estimate Lowered by HC Wainwright

SOPHiA GENETICS SA (NASDAQ:SOPH) – Equities researchers at HC Wainwright lowered their Q3 2026 EPS estimates for SOPHiA GENETICS in a report issued on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.77) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.02) EPS.

Several other research firms have also recently commented on SOPH. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $6.69 on Friday. The business’s 50-day moving average price is $5.57 and its 200 day moving average price is $5.13. SOPHiA GENETICS has a twelve month low of $2.96 and a twelve month high of $7.21. The company has a market capitalization of $561.22 million, a PE ratio of -5.82 and a beta of 0.96. The company has a current ratio of 2.69, a quick ratio of 1.90 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the completion of the sale, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00. Following the completion of the transaction, the insider directly owned 600,887 shares in the company, valued at approximately $4,158,138.04. This represents a 1.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 256,092 shares of company stock valued at $1,492,420 over the last ninety days. Corporate insiders own 4.88% of the company’s stock.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. purchased a new position in SOPHiA GENETICS in the second quarter valued at about $567,000. Royal Bank of Canada boosted its position in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the period. Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS in the first quarter worth about $1,772,000. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares in the last quarter. Finally, Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $2,157,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, implying 22%–24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. Management continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The partnership could expand SOPH’s commercial reach and provide longer-term growth opportunities. SOPHiA GENETICS AstraZeneca partnership article
• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target from $12 to $14. BTIG Research also maintained a Buy rating and lifted its target from $8 to $9, signaling improved confidence in the company’s growth prospects.
• Positive Sentiment: Second-quarter revenue rose 27% year over year to $23.31 million, surpassing the $21.72 million consensus estimate. The adjusted EBITDA loss also improved by 27% to $8.8 million.
• Neutral Sentiment: HC Wainwright reduced its FY2029 EPS estimate to $0.31 from $0.34 but increased its FY2030 forecast to $0.72 from $0.69. The firm’s $14 target and Buy rating were unchanged, suggesting near-term forecast pressure but stronger longer-term expectations.
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu sold a combined 35,000 shares for approximately $242,350 under pre-arranged Rule 10b5-1 plans. Their remaining ownership stakes declined only modestly, reducing the significance of the sales as a bearish signal.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the expected $0.21 loss. The company remains deeply unprofitable, with a negative net margin and analysts forecasting a full-year loss of approximately $0.58 per share.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.